Our Company
LIPOCI is a Vietnamese Research and Development biotechnology company
Established on July 23rd, 2024, LIPOCI aspires to be a cutting-edge research and development (R&D) company, we emerged from a unique partnership with Pharmacist Ms DAO Thi Kim Dung, a dedicated Vietnamese scientist and researcher with over two decades of experience in scientific innovation.
Her commitment to research and therapeutic development has led to the creation of a complex phospholipid formula, PL-PRO-OIL.
Leveraging PL-PRO-OIL formula, PD-Curcumin is specifically designed for multiple skin wound treatment applications. This innovative technology focuses on improving the healing of skin tissue damage caused by burns, ulcers, and various other skin conditions, while also addressing metabolic disorders.
Our Innovation
- PL-PRO-OIL: an innovative Phospholipid Complex optimized for pharmaceutical application,
- PD-Curcumin: a nano-liquid composition specifically designed for therapeutic applications in treating various types of skin wounds, such as burns and ulcers.
Our Mission
Commitment to Safe, Sustainable Health Care Solutions
LIPOCI is dedicated to advancing wound care solutions and human health care preparations that prioritize both safety and environmental sustainability. The company is committed to improving human health through innovative products that meet the highest standards of efficacy and safety. In addition to the current breakthroughs, LIPOCI has a pipeline of other high-quality biological products to be announced and launched in the near future. As part of its vision, LIPOCI is focused on building a sustainable business that is responsible to both the community and society, ensuring long-term positive impact on global health.
Our Assets
LIPOCI is the exclusive Licensee of the “Burns and Ulcers Patent” no US 12,150.919 B2, granted to DKD International Production JSC, by the United States Patent and Trademark Office (“USPTO”) on Nov. 26th, 2024.
LIPOCI is also the exclusive global distributor of the “Patent No. US 18/757.539 (soon to be published by Dec. 24th, 2024) focusing on an innovative phospholipid complex technology designed to enhance liposomal drug delivery system.